AKUMS
Akums Drugs and Pharmaceuticals Limited (AKUMS) Stock Analysis
Akums Drugs and Pharmaceuticals Limited is an Indian contract manufacturer of pharmaceutical formulations. It produces medicines for domestic and global clients across dosage forms and therapies. The company is among the larger CDMO players listed in India. It serves generic and innovator customers from multiple plants.
Healthcare › Drug Manufacturers - Specialty & Generic
₹770.00
-6.39% 1W | +62.10% 52W
Market Cap
11.8k CR
P/E Ratio
41.4
52W High
₹838.8
52W Low
₹409.3
Div. Yield
0.13%
Beta
0.6
50 DMA
₹767
200 DMA
₹590.8
Profit Margin
6.5%
Inst. Own.
12.5%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | -13% | 13% | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% |
| Other Income | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 18% | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% |
| Net Profit | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS in Rs | -13.16 | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |
| Metric | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 |
| Expenses | 1,340 | 1,507 | 2,240 | 2,485 | 3,761 | 3,361 | 4,055 | 3,654 | 3,837 | 3,934 |
| Operating Profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 8% | 9% | 7% | 9% | -2.4% | 8% | 3.0% | 11% | 12% | 13% |
| Other Income | 6 | 6 | 26 | 11 | 7 | 15 | 8 | 69 | 108 | 112 |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 | 94 | 96 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 | 155 | 159 |
| Profit before tax | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 | 382 | 426 |
| Tax % | 51% | 50% | 62% | 28% | 30% | 35% | -102% | 0% | 33% | |
| Net Profit | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS in Rs | 366.55 | 523.23 | 335.61 | 943.49 | -35.30 | 6.63 | -0.28 | 21.49 | 16.21 | 18.53 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 18% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 6.0% | 10.0% | 10.0% |
| Profit CAGR | 29.0% | 16.0% | 16.0% |
Shareholding Pattern
Promoters75.26%
FIIs4.24%
DIIs8.85%
Public8.92%
Promoters75.26%
FIIs2.27%
DIIs9.28%
Public10.46%
Promoters75.26%
FIIs1.14%
DIIs14.41%
Public6.45%
Promoters75.26%
FIIs1.38%
DIIs14.36%
Public6.29%
Promoters75.26%
FIIs1.91%
DIIs13.44%
Public6.67%
Promoters75.26%
FIIs5.77%
DIIs7.39%
Public8.84%
Promoters75.26%
FIIs1.38%
DIIs14.36%
Public6.29%
Promoters75.26%
FIIs1.91%
DIIs13.44%
Public6.67%
AKUMS
Holdings Analysis
Key strengths & risk signals
76
Overall
78
Fundamental
75
Technical
Risks (2)
LOW MARGIN! 6.5% profit margin - thin profits.
WEAK MOMENTUM! Limited price growth - -5.6% (1 week), -0.9% (1 month), 11.2% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (765.6) is above 200-day average (589.3) - positive signal.
EXCELLENT YEAR! Stock gained 63.6% in the last year.
STRONG! Trading at 83.8% of 52W range - near yearly highs.
Fundamental & Technical Analysis
76Overall
78Fundamental
75Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 7.0% (MODERATE, 8/15). Profit CAGR: 39.1% (EXCELLENT, 15/15).
Profit Margin
3/10
LOW MARGIN! 6.5% profit margin - thin profits.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.06 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.13% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 7.14% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (767.0) is above 200-day average (590.8) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (770.0) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 62.1% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 308,481 vs down days: 268,701. Ratio: 1.15x
RSI
3/5
NEUTRAL! RSI at 47.1 - balanced momentum.
52W Range
5/5
STRONG! Trading at 84.0% of 52W range - near yearly highs.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -6.4% (1 week), -0.8% (1 month), 12.7% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
AKUMS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-13 | Concall PDF | |
| Q4FY262026-05-21 | Concall PDF | |
| Q3FY262026-02-19 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKUMS | ₹770.00 | 41.4 | 6.5% | 7.0% | 39.1% | +62.1% | 76 | BREAKDOWN | +57.5% | +18.2% | +13.9% | +0.8% |
| SUDEEPPHRM | ₹1,055.20 | 64.7 | 27.0% | 14.4% | 40.5% | +30.7% | 73 | BREAKDOWN | +31.8% | -17.0% | +26.7% | -13.2% |
| VIYASH | ₹233.00 | 57 | 5.9% | 33.3% | – | +10.2% | 60 | BOUNCE FROM SUPPORT | +107.2% | +26.5% | +19.6% | +2.9% |
| STAR | ₹1,084.80 | 16.3 | 12.3% | 8.7% | – | +37.8% | 68 | BREAKDOWN | +57.5% | +23.6% | +13.0% | -4.4% |
| NATCOPHARM | ₹782.60 | 12.4 | 32.8% | 14.5% | 25.6% | -3.8% | 66 | BREAKDOWN | -57.0% | -22.9% | -44.7% | -0.5% |
| SEQUENT | ₹201.20 | 123.4 | 2.5% | 3.1% | -18.9% | +26.2% | 55 | CONSOLIDATION | -13.9% | +161.2% | +10.9% | +102.5% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| PGHL | ₹5,232.50 | 24.3 | 24.9% | 8.2% | 19.3% | -15.7% | 76 | BREAKOUT | +45.3% | +1.7% | +7.4% | -1.8% |
Data from TradeAlone · Updated daily
AKUMS News
Akums Drugs and Pharmaceuticals Limited (AKUMS) breaks out, gains 5% intraday2026-08-10Akums Drugs and Pharmaceuticals Limited (akums) Q1 FY27: Revenue Up 13.9% Yoy2026-08-08Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS) gains 5% intraday2026-08-07Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS) breaks out, moves up 5% intraday2026-07-10Akums Drugs and Pharmaceuticals Limited (akums) Q4 FY26: Revenue Up 9.7%, Ebitda Surges 61.6%2026-05-14
